Synbio International Inc. announced it will conduct clinical trials to validate NIMS™ (Non-invasive Mental Screening), an AI-powered facial analysis technology developed by FacialDx Inc. for detecting depressive symptoms.
Key Points
The technology analyzes facial features from high-definition images captured via mobile devices or desktop computers to identify signs of depression rapidly and cost-effectively. Under a Clinical Trial License Agreement, Synbio will undertake a retrospective feasibility study, followed potentially by a larger prospective validation trial.
“We are thrilled to announce our collaboration to validate and commercialize NIMS,” company leadership said, with the goal of making mental health evaluations more accessible through early detection.
Innovation Foundation
NIMS™ builds on more than 40 years of medical research by Dr. Todd Frisch, using machine learning to detect subtle facial indicators of behavioral conditions and providing objective, physiological analysis that complements traditional diagnostic approaches.
Market Strategy
Synbio plans to engage medical practitioners, corporate partners (aviation, law enforcement, emergency services, veterans’ affairs), and direct consumers. The U.S. medical device market is projected to reach $6.45 billion by 2029, creating significant opportunity for innovative diagnostic tools.
Regulatory Path
FDA approval will be pursued to ensure NIMS™ meets medical and ethical standards, with clinical trial results supporting regulatory submissions.
This release may contain forward-looking statements within the meaning of applicable securities laws, including statements regarding Synbio International Inc.’s business strategy, product development, clinical trial plans, and future operations. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and readers should not place undue reliance on them. Synbio undertakes no obligation to update any forward-looking statement except as required by law.
For informational purposes only — this release is republished from the company’s official disclosures and public news distribution. Investors should refer to Synbio International’s filings on the Investors page and on OTC Markets for complete and current information.